更新于：2024-11-21

Non-antibiotic antibacterials (GEn1E Lifesciences/University of Maryland, Baltimore)

更新于：2024-11-21

概要

研发状态

概要

基本信息

药物类型

重组蛋白

别名

non-antibiotic antibacterials (GEn1E Lifesciences/University of Maryland, Baltimore)

靶点

EpCAM

作用机制

EpCAM抑制剂(上皮细胞粘附分子抑制剂)

治疗领域

感染

在研适应症-

非在研适应症

假单胞菌感染

原研机构

University of Maryland Baltimore

在研机构-

非在研机构

GEn1E Lifesciences, Inc.初创企业

University of Maryland Baltimore

最高研发阶段无进展临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 Non-antibiotic antibacterials (GEn1E Lifesciences/University of Maryland, Baltimore) 相关的临床结果

登录后查看更多信息

100 项与 Non-antibiotic antibacterials (GEn1E Lifesciences/University of Maryland, Baltimore) 相关的转化医学

登录后查看更多信息

100 项与 Non-antibiotic antibacterials (GEn1E Lifesciences/University of Maryland, Baltimore) 相关的专利（医药）

登录后查看更多信息

项与 Non-antibiotic antibacterials (GEn1E Lifesciences/University of Maryland, Baltimore) 相关的文献（医药）

2024-07-01·Brazilian Journal of Otorhinolaryngology

Non-antibiotic antimicrobial agents for chronic rhinosinusitis: a narrative review

Review

作者: Valera, Fabiana Cardoso Pereira ; Caetano, Joao Vitor Bizinoto ; Anselmo-Lima, Wilma T ; Tamashiro, Edwin

OBJECTIVEThis narrative review explores alternative non-antibiotic antimicrobial agents for CRS management in adults.METHODSAlternative antimicrobial agents using EPOS 2020 guidelines as reference were selected, and articles dated from 2003 to 2022 in English, Portuguese, or Spanish using PubMed and EMBASE databases. The parameters analyzed included study design, evidence level, population characteristics, CRS characteristics, interventions, outcomes, sample size, randomization, blinding, and side effects. Reviews, unrelated contexts,in vitro experiments, and duplicates were excluded.RESULTS148 articles were screened; 19 articles were selected for analysis. Randomized controlled trials and cohort studies assessing non-antibiotic antimicrobial treatments for CRS were included. Xylitol demonstrated effectiveness in reducing CRS symptoms, particularly SNOT-22 scores, surpassing saline irrigation benefits. Manuka honey showed potential microbiological benefits in recalcitrant CRS, but symptomatic and endoscopic improvements remained inconclusive. Baby shampoo irrigation improved nasal mucociliary clearance and postoperative outcomes. Colloidal silver nasal irrigation showed limited efficacy in reducing CRS symptoms or endoscopic scores. Povidone-Iodine (PI) nasal irrigation yielded mixed results, with varying effects on culture negativity and SNOT-20 scores. Bacteriophage treatment exhibited promise in decreasing specific bacterial strains and cytokine levels.CONCLUSIONNon-antibiotic antimicrobial therapies, including xylitol, manuka honey, baby shampoo, colloidal silver, PI, bacteriophages, lactoferrin, and carrageenan offer potential alternatives for CRS in adult patients. Xylitol, baby shampoo, and PI presented benefits in improving symptoms and nasal endoscopic scores, however, the number of studies is limited for conclusive recommendations and safety assessments. CRS management should adopt a comprehensive approach, particularly for non-infectious or immune-related cases, moving beyond antibiotics. Antibiotics should be reserved for confirmed bacterial infections. Overall, this review shows the importance of exploring non-antibiotic therapies to enhance the management of CRS.

2010-10-01·Sleep Medicine Reviews1区 · 医学

Dopaminergic augmentation of restless legs syndrome

1区 · 医学

Review

作者: Anne-Marie Williams ; Diego García-Borreguero

Dopaminergic agents are the first-line treatment of restless legs syndrome (RLS), and have been used for the treatment of this disorder since the 1980s. The major issue with this class of drugs is augmentation of RLS symptoms during treatment. The first report of augmentation found an occurrence among 73% of patients treated with levodopa. Subsequent studies have reported somewhat lower incidences, but augmentation remains a clinically significant issue with all dopaminergic agents. It was not until 2007 that an operational, empirical definition of augmentation (Max Planck Institute Criteria) was made. This late development and the fact that studies have not been specifically designed to assess augmentation, have made it particularly difficult to compare the incidence rates for the different RLS treatments. As the primary neural and molecular substrates underlying idiopathic RLS are not known, the pathophysiology of augmentation remains unclear, however there are several hypotheses that concern the role of dopaminergic hyperstimulation, of iron deficiency, the genetic component, the effect of a reduction in responsiveness of tubero-infundibular dopamine receptors, and the role of chronobiotic mechanisms. RLS is treated by maintaining low doses of dopaminergic agents and ensuring iron sufficiency. Non-dopaminergics and opiates can be used when patients experience augmentation with more than one dopaminergic agent.

2009-07-01·Journal of Neurology2区 · 医学

Anticonvulsant hypersensitivity syndrome presenting as aseptic meningitis

2区 · 医学

Letter

作者: Oliver Lily ; Farooq Maniyar ; Rohit Bazaz ; Chris Rooney

Anticonvulsant hypersensitivity syndrome (AHS) is a rare, potentially life-threatening drug reaction which usually occurs after exposure to aromatic antiepileptics. AHS secondary to non-aromatic antiepileptics is even more rare and there are only few case reports of AHS presenting as aseptic meningitis. We present the case of a 48-year-old patient who presented with meningism within 3 weeks of adding lamotrigine for control of her juvenile myoclonic epilepsy. When lamotrigine was restarted 2 weeks later she developed similar but more severe symptoms which resolved on stopping lamotrigine. Our patient was subsequently rendered seizure free on levetiracetam which has not so far been linked with this syndrome. It is important to be aware of this life-threatening complication associated with the use of antiepileptics.

100 项与 Non-antibiotic antibacterials (GEn1E Lifesciences/University of Maryland, Baltimore) 相关的药物交易

登录后查看更多信息